Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Changshu Cao"'
Autor:
Changshu Cao1,2 tcaocs@jnu.edu.cn, Bailian Liu3 liubailan@sohu.com, Chengwu Zeng2 bio-zcw@163.com, Yuhong Lu4 yhlu2001@hotmail.com, Shaohua Chen2 jnshaohuachen@163.com, Lijian Yang2 jnyanglijian@163.com, Bo Li2 jnlibo517@163.com, Yaolan Li3 liyaolan17@126.com, Yangqiu Li2,5 yangqiuli@hotmail.com
Publikováno v:
Cancer Cell International. 2014, Vol. 14 Issue 1, p137-154. 18p.
Autor:
Sichu Liu, Yu Chen, Yangqiu Li, Shaohua Chen, Qi Shen, Bo Li, Chengwu Zeng, Xiuli Wu, Changshu Cao, Lijian Yang
Publikováno v:
Journal of Hematology & Oncology
We reported that knockdown of PPP2R5C by siRNA led to proliferation inhibition and apoptosis induction in K562 cells. In this study, we further characterized the gene expression profiles after PPP2R5C suppression by microarray analysis. Genes which p
Publikováno v:
China Journal of Chinese Materia Medica.
OBJECTIVE To research the cytotoxicity and in vitro antiproliferative effect of the six flavone compounds extracted from Laggera pterodonta. METHOD The cytotoxicity on the normal cells and antiproliferative effect on tumor cells were tested by MTT as
Publikováno v:
Experimental Neurology. :194-208
Despite the obvious clinical interest, our understanding of how developmental mechanisms are redeployed during degeneration and regeneration after brain and spinal cord injuries remains quite rudimentary. In animal models of spinal cord injury, altho
Autor:
Bailian Liu, Yangqiu Li, Yuhong Lu, Bo Li, Changshu Cao, Chengwu Zeng, Yaolan Li, Shaohua Chen, Lijian Yang
Publikováno v:
Cancer Cell International
Background Treatment with imatinib mesylate (IM) (a tyrosine kinase inhibitor) is the first line of standard care for patients newly diagnosed with CML. Despite the success of IM and other tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (